stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) EPS (diluted)
BridgeBio Pharma, Inc.'s EPS (diluted) for fiscal 2025 was −$3.78, compared with −$2.88 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$3.04. Over the past ten years it has ranged from −$3.95 (fiscal 2023) to −$1.00 (fiscal 2017); the current reading is higher than 44% of that period. BridgeBio Pharma, Inc. ranks 374th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.78 | — |
| FY2024 | −$2.88 | — |
| FY2023 | −$3.95 | — |
| FY2022 | −$3.26 | — |
| FY2021 | −$3.90 | — |
| FY2020 | −$3.80 | — |
| FY2019 | −$2.48 | — |
| FY2018 | −$2.12 | — |
| FY2017 | −$1.00 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.42 | — |
| Jun 2026 | −$0.78 | — |
| Mar 2026 | −$0.84 | — |
| Dec 2025 | −$1.00 | — |
| 28 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ASND Ascendis Pharma A/S compare | $12.89 |
| HALO Halozyme Therapeutics, Inc. compare | $3.93 |
| EXEL Exelixis, Inc. compare | $3.34 |
| JAZZ Jazz Pharmaceuticals PLC compare | $2.95 |
| TECH Bio-Techne Corp compare | $1.15 |
| BMRN BioMarin Pharmaceutical Inc. compare | −$0.10 |
| SMMT Summit Therapeutics PLC compare | −$1.12 |
| BBIO BridgeBio Pharma, Inc. | −$3.04 |
| KYMR Kymera Therapeutics, Inc. compare | −$3.62 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BBIO
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement